0001654954-23-015436.txt : 20231213 0001654954-23-015436.hdr.sgml : 20231213 20231212200923 ACCESSION NUMBER: 0001654954-23-015436 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231212 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 231482726 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 8-K 1 aimd_8k.htm FORM 8-K aimd_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________

 

FORM 8-K

__________________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 12, 2023

__________________________

 

AINOS, INC.

(Exact name of registrant as specified in its charter)

__________________________

 

Texas

 

0-20791

 

75-1974352

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

8880 Rio San Diego Drive, Ste. 800, San Diego, CA 92108

(858) 869-2986

(Address and telephone number, including area code, of registrant's principal executive offices)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

AIMD

 

The Nasdaq Stock Market LLC

Warrants to purchase Common Stock

 

AIMDW

 

The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 8.01.  Other Events.

 

As previously reported in the Definitive Information Statement on Schedule 14C of Ainos, Inc. (the “Company”), as filed with the Securities and Exchange Commission on October 27, 2023, the holders of approximately 66.40% of the Company’s then-issued and outstanding common stock, par value $0.01 (the “Common Stock”), adopted and approved a written consent on October 11, 2023, approving, among other items, a reverse stock split of the Common Stock at a ratio not more than 5:1 (the “Reverse Stock Split”), the exact exchange ratio of the Reverse Stock Split to be determined by the Company’s Chief Executive Officer in his sole discretion.

 

On November 14, 2023, the Company’s Chief Executive Officer approved by written consent a ratio of 1-for-5 for the Reverse Stock Split. The Company filed a Certificate of Amendment to its Restated Certificate of Formation on November 27, 2023, to effect the stock consolidation on December 14, 2023, at 8:00 a.m., Central time.

 

The new shares of Common Stock will be effective for trading purposes as of the commencement of trading on Thursday, December 14, 2023, and will trade under a new CUSIP number 00902F 303. The Company’s ticker symbol, AIMD, will remain unchanged.

 

The new number of outstanding shares of Common Stock  will be approximately 4,677,898 shares. The number of authorized shares and the par value per share will remain unchanged. No fractional shares will be issued in connection with the Reverse Stock Split. Holders of fractional shares will be paid out in cash for the fractional portion. The number of outstanding options and warrants will be adjusted accordingly, with outstanding options being approximately 7,333 and outstanding warrants being approximately 664,730.

 

The Company’s stockholders will receive instructions from the Company’s transfer agent, Equiniti Trust Company, LLC relating to procedures for exchanging existing stock certificates for new certificates or book-entry shares and for the receipt of cash proceeds in lieu of fractional shares.

 

On December 12, 2023, the Company issued a press release announcing the timing of the Reverse Stock Split. A copy of that press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit

 

Description

 

 

 

99.1

 

Press Release dated December 12, 2023.

104

 

Cover Page Interactive Data File (formatted as Inline XBRL).

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Ainos, Inc.

 

 

 

 

 

Date:  December 12, 2023

By:

/s/ Chun-Hsien Tsai           

 

 

 

Name:  Chun-Hsien Tsai  

 

 

 

Title:    Chief Executive Officer 

 

 

 

3

 

 EX-99.1 2 aimd_ex991.htm EX-99.1 aimd_EX991.htm

EXHIBIT 99.1

 

Ainos,Inc. Announces Stock Consolidation

 

SAN DIEGO, CA, December 12, 2023 – Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos,” or the “Company”), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding shares of common stock on the basis of one (1) new share of common stock for every five (5) currently outstanding shares.

 

The new shares of common stock will be effective for trading purposes as of the commencement of trading on Thursday, December 14, 2023, and will trade under a new CUSIP number 00902F 303. The Company’s ticker symbol, AIMD, will remain unchanged. The Company has filed a Certificate of Amendment to its Restated Certificate of Formation to effect the stock consolidation.

 

The new number of outstanding common shares will be approximately 4,677,898 shares. The number of authorized shares and the par value per share will remain unchanged. No fractional shares will be issued in connection with the reverse stock split. Holders of fractional shares will be paid out in cash for the fractional portion. The number of outstanding options and warrants will be adjusted accordingly, with outstanding options being approximately 7,333 and outstanding warrants being approximately 664,730.

 

Ainos stockholders will receive instructions from the Company’s transfer agent, Equiniti Trust Company, LLC relating to procedures for exchanging existing stock certificates for new certificates or book-entry shares and for the receipt of cash proceeds in lieu of fractional shares.

 

About Ainos, Inc.

 

Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose VELDONA® interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. The lead POCT candidate, Ainos Flora, is intended to be a telehealth-friendly POCT for women's health and certain common sexually transmitted infections ("STIs"). To learn more, visit https://www.ainos.com.

 

Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” about Ainos within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “project,” “target,” “future,” “likely,” “strategy,” “foresee,” “may,” “guidance,” “potential,” “outlook,” “forecast,” “should,” “will” or other similar words or phrases. Similarly, statements that describe the Company’s objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements are based only on the Company’s current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results may differ materially from those indicated in the forward-looking statements.

 

 

 

 

Important factors that could cause the Company’s actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release include, among others, the cost of production and sales potential of the planned drug treatments announced in this press release; the Company’s dependence on revenues from the sale of COVID-19 test kits and VELDONA Pet supplements; the Company’s limited cash and history of losses; the Company’s ability to achieve profitability; the Company’s ability to raise additional capital to continue the Company’s product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos’ current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company’s current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company’s industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company’s operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company’s ability to realize the benefits of third party licensing agreements; the Company’s ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations and tariffs; and the Company’s success in managing the growth. A more complete description of these risk factors and others is included in the “Risk Factors” section of Ainos’ most recent Annual Report on Form 10-K/A and other reports filed with the U.S. Securities and Exchange Commission, many of which risks are beyond the Company’s control. In addition to the risks described above, and in the Company’s Annual Report on Form 10-K/A, other unknown or unpredictable factors also could cause actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this press release.

 

The forward-looking statements made in this press release are expressly qualified in their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly update or revise any forward-looking statement to reflect changed assumptions, the occurrence of anticipated or unanticipated events or changes to the future results over time or otherwise, except as required by law.

 

Investor Relations Contact

ICR, LLC

Robin Yang

Tel: +1 646-224-6971

Email: Ainos.IR@icrinc.com

 

 

 

 EX-101.SCH 3 aimd-20231212.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 aimd-20231212_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Class of Stock [Axis] Common Stocks [Member] Warrants Member EX-101.CAL 5 aimd-20231212_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 aimd-20231212_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 aimd-20231212_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 12, 2023
Document Information Line Items  
Entity Registrant Name AINOS, INC.
Entity Central Index Key 0001014763
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Dec. 12, 2023
Entity File Number 0-20791
Entity Incorporation State Country Code TX
Entity Tax Identification Number 75-1974352
Entity Address Address Line 1 8880 Rio San Diego Drive
Entity Address Address Line 2 Ste. 800
Entity Address City Or Town San Diego
Entity Address State Or Province CA
Entity Address Postal Zip Code 92108
City Area Code 858
Local Phone Number 869-2986
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Common Stocks [Member]  
Document Information Line Items  
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol AIMD
Security Exchange Name NASDAQ
Warrants Member  
Document Information Line Items  
Security 12b Title Warrants to purchase Common Stock
Trading Symbol AIMDW
Security Exchange Name NASDAQ
XML 9 aimd_8k_htm.xml IDEA: XBRL DOCUMENT 0001014763 2023-12-12 2023-12-12 0001014763 aimd:CommonStocksMember 2023-12-12 2023-12-12 0001014763 aimd:WarrantsMember 2023-12-12 2023-12-12 iso4217:USD shares iso4217:USD shares 0001014763 false 8-K 2023-12-12 AINOS, INC. TX 0-20791 75-1974352 8880 Rio San Diego Drive Ste. 800 San Diego CA 92108 858 869-2986 Common Stock, par value $0.01 per share AIMD NASDAQ Warrants to purchase Common Stock AIMDW NASDAQ false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

8/ !? MJQ"(6,P$ "(" / M " <\0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " KH8Q7)!Z; MHJT #X 0 &@ @ $O$@ >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " KH8Q799!YDAD! #/ P $P M @ $4$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !> %% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 23 1 false 2 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://aimd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aimd-20231212.xsd aimd-20231212_cal.xml aimd-20231212_def.xml aimd-20231212_lab.xml aimd-20231212_pre.xml aimd_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aimd_8k.htm": { "nsprefix": "aimd", "nsuri": "http://aimd.com/20231212", "dts": { "schema": { "local": [ "aimd-20231212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "aimd-20231212_cal.xml" ] }, "definitionLink": { "local": [ "aimd-20231212_def.xml" ] }, "labelLink": { "local": [ "aimd-20231212_lab.xml" ] }, "presentationLink": { "local": [ "aimd-20231212_pre.xml" ] }, "inline": { "local": [ "aimd_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://aimd.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-12-12to2023-12-12", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "aimd_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-12-12to2023-12-12", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "aimd_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "aimd_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aimd.com/20231212", "localname": "WarrantsMember", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants Member" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://aimd.com/role/Cover" ], "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "aimd_CommonStocksMember": { "xbrltype": "domainItemType", "nsuri": "http://aimd.com/20231212", "localname": "CommonStocksMember", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stocks [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aimd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001654954-23-015436-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-015436-xbrl.zip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